Cyclerion Therapeutics, Inc.CYCNNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank38
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P38
Within normal range
vs 5Y Ago
-0.5x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -10.30% |
| Q2 2025 | 13.78% |
| Q1 2025 | 20.35% |
| Q4 2024 | 0.56% |
| Q3 2024 | -2.97% |
| Q2 2024 | -18.74% |
| Q1 2024 | -20.14% |
| Q4 2023 | -7.51% |
| Q3 2023 | 39.65% |
| Q2 2023 | -43.54% |
| Q1 2023 | -26.53% |
| Q4 2022 | 18.52% |
| Q3 2022 | -11.84% |
| Q2 2022 | -10.91% |
| Q1 2022 | -10.45% |
| Q4 2021 | -4.09% |
| Q3 2021 | -26.28% |
| Q2 2021 | 16.33% |
| Q1 2021 | -26.15% |
| Q4 2020 | -9.56% |
| Q3 2020 | 21.22% |
| Q2 2020 | -3.83% |
| Q1 2020 | -6.69% |
| Q4 2019 | 3.74% |
| Q3 2019 | -20.22% |
| Q2 2019 | -18.71% |
| Q1 2019 | 29.91% |
| Q4 2018 | 8.51% |
| Q3 2018 | 3.41% |
| Q2 2018 | 99.79% |
| Q1 2018 | 29.21% |
| Q4 2017 | -27.74% |
| Q3 2017 | 0.00% |